UM Zanger
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology(DE)
Publications by Year
Research Areas
Immune Response and Inflammation, Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, Pancreatic and Hepatic Oncology Research, Pharmacogenetics and Drug Metabolism
Most-Cited Works
- → Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting(2015)178 cited
- → FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4-5 fluoropyrimidine (FP) toxicity(2019)5 cited
- → Pharmakogenomik:HypeoderHope?(2011)1 cited
- → MK2 mediates induction and sensing of Oncostatin M-induced intercellular signalling in the liver but is dispensable for negative feedback regulation via SOCS3(2015)1 cited
- → 404MO Clinical relevance of MIR27A rs895819 polymorphism and its interaction with DPYD variants for predicting grade 4-5 fluoropyrimidine (FP) toxicity (tox) in the FUSAFE individual patient data meta-analysis (IPD-MA)(2020)
- → Cholestasis is associated with induction of antimicrobial active reduced human β-defensin 1(2016)
- → Identifikation neuer differenziell regulierter Mediatoren im Rahmen der Leberregeneration(2015)
- → Die intrazelluläre Kinase MK2 reguliert die Eisenhomöostase sowie die Expression von Hepcidin als Antwort auf bakterielles Endotoxin(2019)